| | Application no. and date | 18155724.0 (espacenet)  (Federated)  (European Patent Register), 20020218 |  | Patent/reg. no. and date | DK/EP 3342411, 20190821 |  | Publication date | 20180704 |  | Priority no. and date | GB 0104072, 20010219, GB 0124957, 20011017 |  | EP pub. no. and date | EP 3342411 20180704 |  | Effective date |  |  | Applicant/owner | Novartis Pharma AG, Lichtstrasse 35 4002 Basel, CH
 |  | Applicant ref. no. | SH/GP/159228 |  | Inventor | Wood, Jeanette Marjorie, In den Kleematten 18 4105 Biel-Benken, CH,
 Lane, Heidi, Kaltbrunnenweg 8
 4106 Therwill, CH,
 O`Reilly, Terence, Drahtzugstrasse 51
 4057 Basel, CH
 |  | Representative | Budde Schou A/S, Dronningens Tværgade 30, 1302 København K |  | Opponent |  |  | IPC Class | A61K 31/436 (2006.01) ,  A61P 35/00 (2006.01) |  | Title | Rapamycinderivat til behandling af pancreascancer |  | Int. application no. |  |  | Int. publication no. |  |  | Related patent (certificate) | CA 2020 00007 |  | Status | Udløbet |  | Pædiatrisk forlængelse | - |  | Udløbsdato for pædiatrisk forlængelse | - | 
 |